ASCO 2023 – China’s Dizal claims broad coverage with a super-Tagrisso
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
Having impressed two years ago, Dizal returns with even more comprehensive targeted therapy data.
